Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
AC-0676 by Accutar Biotechnology for Follicular Lymphoma: Likelihood of Approval
AC-0676 is under clinical development by Accutar Biotechnology and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
Data Insights
AC-0676 by Accutar Biotechnology for Marginal Zone B-cell Lymphoma: Likelihood of Approval
AC-0676 is under clinical development by Accutar Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...